BioAtla appoints Edward L. Williams to Board of Directors, increases board to 8

BioAtla, Inc.

Board size increased from 7 to 8; Mr. Williams appointed as Class III director effective Dec 16, 2021.
Mr. Williams will serve on the Audit Committee.
Received initial grant of 25,000 stock options vesting over approximately 2 years under 2020 Equity Incentive Plan.
Former SVP Biopharmaceuticals at Novo Nordisk (2006-2017) and VP at Novartis; currently special advisor to CEO of Ascendis Pharma.
Standard indemnification agreement entered; no related-party transactions disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Edward L. Williams

Director

BCAB · BioAtla, Inc.

Effective: 2021-12-16
Filed: December 21, 2021, 6:59 PM ET

On December 16, 2021, the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Edward L. (Eddie) Williams to the Board, effective December 16, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward L. Williams was appointed as Director at BioAtla, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 16, 2021, the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Edward L. (Eddie) Williams to the Board, effective December 16, 2021.

View on SEC.gov

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-363150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.